These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 12720149)

  • 1. Angiogenesis in Waldenstrom's macroglobulinemia.
    Rajkumar SV; Hayman S; Greipp PR
    Semin Oncol; 2003 Apr; 30(2):262-4. PubMed ID: 12720149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis in Waldenström's macroglobulinemia.
    Terpos E; Tasidou A; Kastritis E; Eleftherakis-Papaiakovou E; Gavriatopoulou M; Migkou M; Dimopoulos MA
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):46-9. PubMed ID: 19362971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor and anti-angiogenic peptides as therapeutic and investigational molecules.
    Zachary I
    IDrugs; 2003 Mar; 6(3):224-31. PubMed ID: 12789611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neoplasms and angiogenesis].
    Lewy-Trenda I
    Pol Merkur Lekarski; 2002 Sep; 13(75):225-8. PubMed ID: 12474576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis in pituitary adenomas.
    Yamada S; Takada K
    Microsc Res Tech; 2003 Feb; 60(2):236-43. PubMed ID: 12539178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
    Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
    J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
    Li J; Luo SK; Hong WD; Zhou ZH; Zou WY
    Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis in multiple myeloma.
    Jakob C; Sterz J; Zavrski I; Heider U; Kleeberg L; Fleissner C; Kaiser M; Sezer O
    Eur J Cancer; 2006 Jul; 42(11):1581-90. PubMed ID: 16797965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of bone marrow angiogenesis in multiple myeloma.
    Rajkumar SV; Leong T; Roche PC; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Kyle RA; Gertz MA; Greipp PR
    Clin Cancer Res; 2000 Aug; 6(8):3111-6. PubMed ID: 10955791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
    Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
    Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Waldenström's macroglobulinemia: a clinicopathologic study of 22 cases.
    Andriko JA; Aguilera NS; Chu WS; Nandedkar MA; Cotelingam JD
    Cancer; 1997 Nov; 80(10):1926-35. PubMed ID: 9366295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity.
    Anagnostopoulos A; Eleftherakis-Papaiakovou V; Kastritis E; Tsionos K; Bamias A; Meletis J; Dimopoulos MA; Terpos E
    Br J Haematol; 2007 Jun; 137(6):560-8. PubMed ID: 17451406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow angiogenesis in multiple myeloma: closing in on the loop.
    Molina JR; Rajkumar SV
    Haematologica; 2003 Feb; 88(2):122-4. PubMed ID: 12604399
    [No Abstract]   [Full Text] [Related]  

  • 15. [Angiogenesis and hematologic malignancy].
    Zini JM; Tobelem G
    Bull Cancer; 2007 Jul; 94 Spec No():S241-6. PubMed ID: 17846010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
    Bhatti SS; Kumar L; Dinda AK; Dawar R
    Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma.
    Ribas C; Colleoni GW; Silva MR; Carregoza MJ; Bordin JO
    Eur J Haematol; 2004 Nov; 73(5):311-7. PubMed ID: 15458509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow angiogenesis in multiple myeloma and its correlation with clinicopathological factors.
    Rana C; Sharma S; Agrawal V; Singh U
    Ann Hematol; 2010 Aug; 89(8):789-94. PubMed ID: 20177896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biology of VEGF and its receptors.
    Ferrara N; Gerber HP; LeCouter J
    Nat Med; 2003 Jun; 9(6):669-76. PubMed ID: 12778165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the use of angiogenesis inhibitors in cancer.
    Pinedo HM
    Cancer J; 2001; 7 Suppl 3():S107-8. PubMed ID: 11779080
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.